CorMedix Inc. (NYSE:CRMD) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 4,723,496 shares, a drop of 0.2% from the December 31st total of 4,731,735 shares, Analyst Ratings Net reports. Approximately 13.6% of the company’s stock are sold short. Based on an average daily trading volume, of 289,159 shares, the short-interest ratio is presently 16.3 days.

CorMedix (NYSE:CRMD) opened at 1.77 on Friday. CorMedix has a 12 month low of $1.15 and a 12 month high of $10.40. The company’s market cap is $62.42 million. The company has a 50-day moving average of $1.80 and a 200 day moving average of $2.50.

Several analysts have recently commented on CRMD shares. Roth Capital reduced their target price on CorMedix from $2.75 to $2.50 and set a “neutral” rating for the company in a research note on Monday, November 16th. HC Wainwright initiated coverage on shares of CorMedix in a research report on Thursday, November 12th. They issued a “buy” rating and a $6.50 price target on the stock.

CorMedix Inc. (NYSE:CRMD) is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company’s primary product is Neutrolin, a catheter lock solution, which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. It has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC, a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin, which is in the pre-clinical stage of development.

12 Month Chart for NYSE:CRMD

Receive News & Ratings for CorMedix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.